mPGES-1——一个新的药物开发靶点  

mPGES-1:A New Target for Drug Development

作　　者：郭雷[1] 王淑军[1] 

机构地区：[1]淮海工学院海洋学院,江苏连云港222005

出　　处：《药学进展》2008年第3期103-109,共7页Progress in Pharmaceutical Sciences

基　　金：淮海工学院引进人才基金项目(KQ07026)

摘　　要：综述膜结合型前列腺素E2合酶-1(mPGES-1)的生物学性质、生理和病理作用,以及将其作为一个新的药物作用靶点用于药物开发的可能性。mPGES-1是3种前列腺素E2合酶之一,属于诱导型表达的酶,能被致炎因子诱导而大量表达,在多种疾病,如关节炎、炎症相关性发热和疼痛、动脉粥样硬化及癌症的病理生理过程中均发挥着重要作用。Membrane-associated prostaglandin E2 synthase （mPGES-1） is one of three types of PGES and an inducible enzyme which can be induced by proinflammatory cytokines, mPGES-1 plays an important role in the physiopathology of arthritis, fever and pain associated with inflammation, atherosclerosis and even cancer. In this paper, the biological properties, physiology and physiopathology of mPGES-1 as well as the possibility to be applied into the drug R＆D as a novel target were summarized.

关 键 词：膜结合型前列腺素E2合酶-1 病理生理作用 药物靶点 

分 类 号：R91[医药卫生—药学] Q55[生物学—生物化学]